Posted by Michael Wonder on 21 Jun 2024
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C mutated colorectal cancer
21 June 2024 - Today, the FDA granted accelerated approval to adagrasib (Krazati; Mirati Therapeutics) plus cetuximab for adults with KRAS G12C mutated locally advanced or metastatic colorectal cancer, as determined by an FDA approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Efficacy was evaluated in KRYSTAL-1, a multi-centre, single-arm expansion cohort trial.
